SavedAdd your journal

Journals / Journal of Medical Topics and Updates / 2022 / Cilt: 1 Sayı: 3

Models of spike, envelope and membrane proteins of SARS-CoV-2 variants for possible therapeutics

Olası terapötikler için SARS-CoV-2’nin spike, zarf ve membran proteinlerinin modelleri

Gizem Tutkun(AKDENIZ UNIVERSITY)0000-0002-6184-4974
Ahmet Ozan Özgen(AKDENIZ UNIVERSITY)0000-0001-9516-7927
Uğur Bilge(AKDENİZ ÜNİVERSİTESİ)0000-0002-5186-1092
Pages
133–141
Publication Date
2022-12-23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mutations in the sequence of the three structural proteins of this virus may have a significant impact on the progression of the pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: SARS-CoV-2 associated with severe acute respiratory syndrome is a common, rapidly growing infectious disease with high morbidity and mortality.
📊
Key Findings & Data:Background: SARS-CoV-2 associated with severe acute respiratory syndrome is a common, rapidly growing infectious disease with high morbidity and mortality.
💡
Conclusion & Impact:Mutations in the sequence of the three structural proteins of this virus may have a significant impact on the progression of the pandemic.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:R programlama dili · SARS-CoV-2 · Dizi Hizalama

Abstract

Background: SARS-CoV-2 associated with severe acute respiratory syndrome is a common, rapidly growing infectious disease with high morbidity and mortality. Mutations in the sequence of the three structural proteins of this virus may have a significant impact on the progression of the pandemic.

Özet

Amaç: Şiddetli akut solunum sendromu ile ilişkili SARS-CoV-2, yüksek morbidite ve mortaliteye sahip, yaygın, hızla büyüyen bir enfeksiyon hastalığıdır. Bu virüsün üç yapısal proteininin dizisindeki mutasyonlar, pandeminin ilerlemesi üzerinde önemli bir etkiye sahip olabilir.

🔖

Cite This Article

Tutkun, G., Özgen, A. O., Bilge, U. (2022). Models of spike, envelope and membrane proteins of SARS-CoV-2 variants for possible therapeutics. Journal of Medical Topics and Updates, Cilt: 1 Sayı: 3, 133–141. https://ajindex.com/articles/1618899

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (34)

  1. Alsulami, A. F., Thomas, S. E., Jamasb, A. R., Beaudoin, C. A., Moghul, I., Bannerman, B., Copoiu, L., Vedithi, S. C., Torres, P., & Blundell, T. L. (2021). SARS-CoV-2 3D database: Understanding the coronavirus proteome and evaluating possible drug targets. Briefings in Bioinformatics, 22(2), 769–780. https://doi.org/10.1093/bib/bbaa404
  2. Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Balkhy, H. H., Al Bshabshe, A., Al Jeraisy, M., Mandourah, Y., Azzam, M. H. A., Bin Eshaq, A. M., Al Johani, S., Al Harbi, S., Jokhdar, H. A. A., Deeb, A. M., Memish, Z. A., Jose, J., Ghazal, S., Al Faraj, S., Al Mekhlafi, G. A., Sherbeeni, N. M., … Saudi Critical Care Trials Group. (2020). Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. The New England Journal of Medicine, 383(17), 1645–1656. https://doi.org/10.1056/NEJMoa2015294
  3. Bayrakdar, F., Cosgun, Y., Yalcin, S., & Korukluoglu, G. (2021). HCoV-19/Turkey/HSGM-F10304/2021 (GISAID EpiCoV EPI_ISL_8082633). Ministry of Health Turkey. https://www.epicov.org/epi3/frontend#3f63b7
  4. Buxbaum, E. (2015). Protein Structure. In E. Buxbaum, Fundamentals of Protein Structure and Function (pp. 15–64). Springer International Publishing. https://doi.org/10.1007/978-3-319-19920-7_2
  5. Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., Wang, J., Wang, Y., Niu, X., Yang, S., Liang, H., Sun, H., Li, T., Yu, Y., Cui, Q., … Xie, X. S. (2021). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. https://doi.org/10.1038/d41586-021-03796-6
  6. Cao, Y., Yang, R., Lee, I., Zhang, W., Sun, J., Wang, W., & Meng, X. (2021). Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors. Protein Science, 30(6), 1114–1130. https://doi.org/10.1002/pro.4075
  7. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. (n.d.). Retrieved 27 December 2021, from https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
  8. Cubuk, J., Alston, J. J., Incicco, J. J., Singh, S., Stuchell-Brereton, M. D., Ward, M. D., Zimmerman, M. I., Vithani, N., Griffith, D., Wagoner, J. A., Bowman, G. R., Hall, K. B., Soranno, A., & Holehouse, A. S. (2021). The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nature Communications, 12(1), 1936. https://doi.org/10.1038/s41467-021-21953-3
  9. de Oliveira, O. V., Rocha, G. B., Paluch, A. S., & Costa, L. T. (2021). Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. Journal of Biomolecular Structure and Dynamics, 39(11), 3924–3933. https://doi.org/10.1080/07391102.2020.1772885
  10. Enjuanes, L., Smerdou, C., Castilla, J., Antón, I. M., Torres, J. M., Sola, I., Golvano, J., Sánchez, J. M., & Pintado, B. (1995). Development of protection against coronavirus induced diseases. A review. Advances in Experimental Medicine and Biology, 380, 197–211. https://doi.org/10.1007/978-1-4615-1899-0_34
  11. Good, D. J. (2020). A low-cost, in silico nutritional genomics course-based undergraduate research experience applicable to multiple disciplines. Biochemistry and Molecular Biology Education, 48(4), 320–328. https://doi.org/10.1002/bmb.21352
  12. Huang, Y., Yang, C., Xu, X., Xu, W., & Liu, S. (2020). Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41(9), 1141–1149. https://doi.org/10.1038/s41401-020-0485-4
  13. Iannarella, R., Lattanzi, C., Cannata, G., Argentiero, A., Neglia, C., Fainardi, V., Pisi, G., & Esposito, S. (2020). Coronavirus infections in children: From SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features. Acta Biomedica Atenei Parmensis, 91(3), e2020032–e2020032. https://doi.org/10.23750/abm.v91i3.10294
  14. Kardani, K., Bolhassani, A., & Namvar, A. (2020). An overview of in silico vaccine design against different pathogens and cancer. Expert Review of Vaccines, 19(8), 699–726. https://doi.org/10.1080/14760584.2020.1794832
  15. Lee, C. H., & Koohy, H. (2020). In silico identification of vaccine targets for 2019-nCoV. F1000Research, 9, 145. https://doi.org/10.12688/f1000research.22507.2
  16. Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., & Lu, J. (2020). The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. IScience, 23(6), 101160. https://doi.org/10.1016/j.isci.2020.101160
  17. McIntosh, K., Dees, J. H., Becker, W. B., Kapikian, A. Z., & Chanock, R. M. (1967). Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proceedings of the National Academy of Sciences of the United States of America, 57(4), 933–940. https://doi.org/10.1073/pnas.57.4.933
  18. Mousavizadeh, L., & Ghasemi, S. (2021). Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection, 54(2), 159–163. https://doi.org/10.1016/j.jmii.2020.03.022
  19. Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014). Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. The Lancet. Infectious Diseases, 14(11), 1090–1095. https://doi.org/10.1016/S1473-3099(14)70920-X
  20. Portelli, S., Olshansky, M., Rodrigues, C. H. M., D’Souza, E. N., Myung, Y., Silk, M., Alavi, A., Pires, D. E. V., & Ascher, D. B. (2020). Exploring the structural distribution of genetic variation in SARS-CoV-2 with the COVID-3D online resource. Nature Genetics, 52(10), 999–1001. https://doi.org/10.1038/s41588-020-0693-3
  21. Pulliam, J. R. C., Schalkwyk, C. van, Govender, N., Gottberg, A. von, Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021). Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa (p. 2021.11.11.21266068). https://doi.org/10.1101/2021.11.11.21266068
  22. Raghav, S., Ghosh, A., Turuk, J., Kumar, S., Jha, A., Madhulika, S., Priyadarshini, M., Biswas, V. K., Shyamli, P. S., Singh, B., Singh, N., Singh, D., Datey, A., Avula, K., Smita, S., Sabat, J., Bhattacharya, D., Kshatri, J. S., Vasudevan, D., … Sherpa, T. (2020). Analysis of Indian SARS-CoV-2 Genomes Reveals Prevalence of D614G Mutation in Spike Protein Predicting an Increase in Interaction With TMPRSS2 and Virus Infectivity. Frontiers in Microbiology, 11, 2847. https://doi.org/10.3389/fmicb.2020.594928
  23. Scudellari, M. (2021). How the coronavirus infects cells—And why Delta is so dangerous. Nature, 595(7869), 640–644. https://doi.org/10.1038/d41586-021-02039-y
  24. Shamsi, A., Mohammad, T., Anwar, S., Amani, S., Khan, M. S., Husain, F. M., Rehman, Md. T., Islam, A., & Hassan, M. I. (2021). Potential drug targets of SARS-CoV-2: From genomics to therapeutics. International Journal of Biological Macromolecules, 177, 1–9. https://doi.org/10.1016/j.ijbiomac.2021.02.071
  25. Shen, L., Bard, J. D., Triche, T. J., Judkins, A. R., Biegel, J. A., & Gai, X. (2021). Emerging variants of concern in SARS-CoV-2 membrane protein: A highly conserved target with potential pathological and therapeutic implications. Emerging Microbes & Infections, 10(1), 885–893. https://doi.org/10.1080/22221751.2021.1922097
  26. Siu, Y. L., Teoh, K. T., Lo, J., Chan, C. M., Kien, F., Escriou, N., Tsao, S. W., Nicholls, J. M., Altmeyer, R., Peiris, J. S. M., Bruzzone, R., & Nal, B. (2008). The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. Journal of Virology, 82(22), 11318–11330. https://doi.org/10.1128/JVI.01052-08
  27. Swain, S. S., Rout, S. S., Sahoo, A., Oyedemi, S. O., & Hussain, T. (2021). Antituberculosis, antioxidant and cytotoxicity profiles of quercetin: A systematic and cost-effective in silico and in vitro approach. Natural Product Research, 0(0), 1–5. https://doi.org/10.1080/14786419.2021.2008387
  28. Toparslan, E., Karabag, K., & Bilge, U. (2020). A workflow with R: Phylogenetic analyses and visualizations using mitochondrial cytochrome b gene sequences. PLOS ONE, 15(12), e0243927. https://doi.org/10.1371/journal.pone.0243927
  29. Tracking SARS-CoV-2 variants. (2022, May 3). https://www.who.int/activities/tracking-SARS-CoV-2-variants
  30. Troyano-Hernáez, P., Reinosa, R., & Holguín, Á. (2021). Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Viruses, 13(2), 243. https://doi.org/10.3390/v13020243
  31. Vilar, S., & Isom, D. G. (2021). One Year of SARS-CoV-2: How Much Has the Virus Changed? Biology, 10(2), 91. https://doi.org/10.3390/biology10020091
  32. Wormser, G. P., & Aitken, C. (2010). Clinical Virology, 3rd Edition Edited by D. D. Richman, R. J. Whitley, and F. G. Hayden Washington, DC: ASM Press, 2009. 1408 pp, Illustrated. $259.59 (hardcover). Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 50(12), 1692. https://doi.org/10.1086/652862
  33. Zhang, C., Zheng, W., Huang, X., Bell, E. W., Zhou, X., & Zhang, Y. (2020). Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1. Journal of Proteome Research, 19(4), 1351–1360. https://doi.org/10.1021/acs.jproteome.0c00129
  34. Zheng, W., Zhang, C., Li, Y., Pearce, R., Bell, E. W., & Zhang, Y. (2021). Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Reports Methods, 1(3), 100014. https://doi.org/10.1016/j.crmeth.2021.100014